# **IMPLEMENTATION OF A PATIENT STRATIFICATION MODEL IN OUTPATIENT** PHARMACY FOR IMMUNE-MEDIATED DERMATOLOGICAL DISEASES

<sup>1</sup>H. Suñer ; <sup>1</sup>P.A. López Broseta; <sup>1</sup>I. Sacanella Anglés; <sup>1</sup>D. Pascual Carbonell ; <sup>1</sup>C.D Ciuciu; <sup>1</sup>S. Jornet Montaña; <sup>1</sup>I. Plo Seco; <sup>1</sup>M.Á. Roch Ventura; <sup>1</sup>M.F. Vuelta Arce; <sup>1</sup>L. Canadell Vilarrasa.

<sup>1</sup>Pharmacy Department, Hospital Universitari Joan XXIII, Tarragona, Spain




L04- IMMUNOSUPPRESSANTS

# BACKGROUND

To determine **patient follow-up frequency** and target those who benefit most from Pharmaceutical care:

Pharmaceutical Care (PC)






### **AIM AND OBJECTIVES**

То determine the complexity of with immunomediated patients dermatological (IMD) diseases initiating **biological therapy** in our hospital, using

Achieve safe pharmacotherapeutic goals Improving health outcomes

the CMO model, and compare the results obtained with the expected model outcomes reported in the bibliography.

# **MATERIALS AND METHOD**



To determine the complexity level, the CMO model was applied, encompassing 23 variables in demographic, socio-sanitary and cognitive, healthcare service utilization, and treatment-related categories. Patient's total score is calculated by combining the points assigned to each variable.

Data were collected from patient medical records, electronic prescription HOW? dispensing records, and clinical interviews in pharmaceutical care consultations.


> Results were compared with the percentage distribution proposed for each complexity level by the model.


#### RESULTS

Socio-sanitary and cognitive variables

Healthcare service utilization variables


#### Demographic variables






- Atopic dermatitis
- Suppurative hidradenitis






#### **Treatment-related variables**



 $\geq$  2 chronic diseases **29%** 

Moderate/high disease activity 73%



0% 20% 80% 40% 60% 100%

## **CONCLUSION AND RELEVANCE**

Against expectations from the CMO, most patients were in level 2, possibly due to stratification timing, occurring during treatment initiation or changes when patients' diseases were most exacerbated.

Through the CMO application, we identified patients most likely to benefit from PC, enabling us to reallocate resources for more regular follow-up, ensuring comprehensive patient support.

